A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.

NCT02075541 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

145

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Disorders

Interventions

BIOLOGICAL: NTHi-10-AS01E
DRUG: NaCl Placebo

Sponsor

GlaxoSmithKline